CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription

Resistance to temozolomide (TMZ), the first-line chemotherapeutic drug for glioblastoma (GBM) and anaplastic gliomas, is one of the most significant obstacles in clinical treatment. TMZ resistance is regulated by complex genetic and epigenetic networks. Understanding the mechanisms of TMZ resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiang, Liu, Xiaochen, Gao, Min, Gong, Li, Tian, Fei, Shen, Yangli, Hu, Huili, Sun, Gongping, Zou, Yongxin, Gong, Yaoqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050354/
https://www.ncbi.nlm.nih.gov/pubmed/33869025
http://dx.doi.org/10.3389/fonc.2021.638802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050354/
https://www.ncbi.nlm.nih.gov/pubmed/33869025
http://dx.doi.org/10.3389/fonc.2021.638802

Ejemplares similares